Shares of MannKind Corporation climbed more than 2% in premarket trading Wednesday, on track to extend gains from the ...

Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...

Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and ...

MannKind (MNKD) and Cipla announced that the Central Drugs Standard Control Organisation in India has approved Afrezza Inhalation Powder in ...

Cipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, ...

Mumbai: Cipla Limited has announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation ...

Fmr LLC lifted its holdings in shares of MannKind Co. (NASDAQ:MNKD – Free Report) by 0.2% during the 3rd quarter, according ...

On Monday, MannKind Corp (MNKD) stock saw a decline, ending the day at $6.66 which represents a decrease of $-0.14 or -2.06% from the prior close of $6.8. The stock opened at $6.81 and touched a low ...

On Monday, MannKind Corp (MNKD) stock saw a decline, ending the day at $6.59 which represents a decrease of $-0.19 or -2.80% from the prior close of $6.78. The stock opened at $6.75 and touched a low ...